SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2009
Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 5 syntheses or guidelines pooled it, 223 citations in OpenAlex.
- Reinfection rate of hepatitis C in HIV-1 positive men who have sex with men: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Pooled it
- Recommendations for the management of hepatitis C virus infection among people who inject drugs.The International journal on drug policy · 2015Guideline
- Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Pooled it
- Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment.AIDS (London, England) · 2013Pooled it
- Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.Pharmacology research & perspectives · 2017Trial
- Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era.PloS one · 2017Trial
- Reasons for drinking as predictors of alcohol involvement one year later among HIV-infected individuals with and without hepatitis C.Annals of medicine · 2016Trial
- IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.PloS one · 2011Trial
- A novel model of care; Telemedicine and peer support for HCV care among HIV-infected people who inject drugs in remote Myanmar: a retrospective study.Harm reduction journal · 2026Article
- Treatment Outcomes of HCV Infection in People Living with HIV: A Case Series from a Single Center in Korea.Infection & chemotherapy · 2024Article
- Hepatitis C Virus Elimination in the United States: Challenges, Progress, and Future Steps.Gastroenterology & hepatology · 2023Article
- Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics.Public health reports (Washington, D.C. : 1974) · 2023Review
- Increased All-cause Mortality in People With HIV and Comorbidities: Hepatitis B and C Virus Seropositivity and Hyperglycemia in Myanmar, 2005-2017.Open forum infectious diseases · 2023Article
- Implication of COVID-19 in patients of HIV with hepatitis C.Journal of family medicine and primary care · 2022Article
- Hepatitis C virus: A critical approach to who really needs treatment.World journal of hepatology · 2022Review
- Mortality among clients in the New York city HIV Care Coordination Program (CCP): incidence and associated clinical factors.Annals of epidemiology · 2021Article
- CCR5+ T-Cells Homed to the Liver Exhibit Inflammatory and Profibrogenic Signatures in Chronic HIV/HCV-Coinfected Patients.Viruses · 2021Article
- Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.AIDS patient care and STDs · 2021Article
- Adherence to clinical follow-up recommendations for liver function tests: A cross-sectional study of patients with HCV and their associated risk behaviors.Preventive medicine reports · 2021Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIt is unclear whether coinfection with hepatitis C virus (HCV) increases mortality in patients with human immunodeficiency virus (HIV) infection during the era of highly active antiretroviral therapy (HAART). With use of a meta-analysis, we estimated the effect of HCV infection on HIV disease progression and overall mortality in the pre-HAART and HAART eras.
methodThe PubMed and EMBASE databases were searched for studies published through 30 April 2008. Additional studies were identified from cited references. Studies reporting disease progression or mortality among HCV-HIV coinfected patients were selected. Cross-sectional studies, studies without HCV-negative control subjects, and studies involving children and/or patients who had undergone liver transplantation were excluded. Two authors reviewed articles and extracted data on the demographic characteristics of study populations and risk estimates. Meta-regression was used to explore heterogeneity.
resultsTen studies from the pre-HAART era and 27 studies from the HAART era were selected. In the pre-HAART era, the risk ratio for overall mortality among patients with HCV-HIV coinfection, compared with that among patients with HIV infection alone, was 0.68 (95% confidence interval [CI], 0.53-0.87). In the HAART era, the risk ratio was 1.12 (95% CI, 0.82-1.51) for AIDS-defining events and 1.35 (95% CI, 1.11-1.63) for overall mortality among coinfected patients, compared with that among patients with HIV monoinfection.
conclusionsHCV coinfection did not increase mortality among patients with HIV infection before the introduction of HAART. In contrast, in the HAART era, HCV coinfection, compared with HIV infection alone, increases the risk of mortality, but not the risk of AIDS-defining events. Future studies should determine whether successful treatment of HCV infection could reduce this excess risk of mortality in coinfected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.